338 related articles for article (PubMed ID: 28407088)
1. Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification.
Gilbert JW; Wolpin B; Clancy T; Wang J; Mamon H; Shinagare AB; Jagannathan J; Rosenthal M
Ann Oncol; 2017 Sep; 28(9):2067-2076. PubMed ID: 28407088
[TBL] [Abstract][Full Text] [Related]
2. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy.
Jang JK; Byun JH; Kang JH; Son JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Kim SC; Lee MG
Eur Radiol; 2021 Feb; 31(2):813-823. PubMed ID: 32845389
[TBL] [Abstract][Full Text] [Related]
3. Tumor resectability and response on CT following neoadjuvant therapy for pancreatic cancer: inter-observer agreement study.
Kim HY; Lee YJ; Chang W; Cho J; Park JH; Lee JC; Kim J; Hwang JH; Kim YH
Eur Radiol; 2022 Jun; 32(6):3799-3807. PubMed ID: 35032213
[TBL] [Abstract][Full Text] [Related]
4. High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study.
Lee DH; Ha HI; Jang JY; Lee JW; Choi JY; Bang S; Lee CH; Kim WB; Lee SS; Kim SC; Kang BK; Lee JM
Eur Radiol; 2023 Sep; 33(9):5965-5975. PubMed ID: 36988715
[TBL] [Abstract][Full Text] [Related]
5. How to approach pancreatic cancer after neoadjuvant treatment: assessment of resectability using multidetector CT and tumor markers.
Jeon SK; Lee JM; Lee ES; Yu MH; Joo I; Yoon JH; Jang JY; Lee KB; Lee SH
Eur Radiol; 2022 Jan; 32(1):56-66. PubMed ID: 34170366
[TBL] [Abstract][Full Text] [Related]
6. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part I, AJCC staging system, NCCN guidelines, and borderline resectable disease.
Kulkarni NM; Soloff EV; Tolat PP; Sangster GP; Fleming JB; Brook OR; Wang ZJ; Hecht EM; Zins M; Bhosale PR; Arif-Tiwari H; Mannelli L; Kambadakone AR; Tamm EP
Abdom Radiol (NY); 2020 Mar; 45(3):716-728. PubMed ID: 31748823
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Therapy: When Should It Be Used for Pancreatic Cancer?
Kelly KN; Macedo FI; Merchant NB
Adv Surg; 2020 Sep; 54():49-68. PubMed ID: 32713439
[No Abstract] [Full Text] [Related]
8. Staging of pancreatic cancer: resectable, borderline resectable, and unresectable disease.
Soloff EV; Zaheer A; Meier J; Zins M; Tamm EP
Abdom Radiol (NY); 2018 Feb; 43(2):301-313. PubMed ID: 29198002
[TBL] [Abstract][Full Text] [Related]
9. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
[TBL] [Abstract][Full Text] [Related]
10. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.
Ferrone CR; Marchegiani G; Hong TS; Ryan DP; Deshpande V; McDonnell EI; Sabbatino F; Santos DD; Allen JN; Blaszkowsky LS; Clark JW; Faris JE; Goyal L; Kwak EL; Murphy JE; Ting DT; Wo JY; Zhu AX; Warshaw AL; Lillemoe KD; Fernández-del Castillo C
Ann Surg; 2015 Jan; 261(1):12-7. PubMed ID: 25599322
[TBL] [Abstract][Full Text] [Related]
11. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.
Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M;
BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786
[TBL] [Abstract][Full Text] [Related]
12. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
[TBL] [Abstract][Full Text] [Related]
13. A patient-centered, multidisciplinary approach to treating borderline resectable pancreatic adenocarcinoma.
Hester CA; Katz MHG
Chin Clin Oncol; 2022 Dec; 11(6):45. PubMed ID: 36509553
[TBL] [Abstract][Full Text] [Related]
14. Pancreatic adenocarcinoma: A simple CT score for predicting margin-positive resection in patients with resectable disease.
Cassinotto C; Dohan A; Zogopoulos G; Chiche L; Laurent C; Sa-Cunha A; Cuggia A; Reinhold C; Gallix B
Eur J Radiol; 2017 Oct; 95():33-38. PubMed ID: 28987689
[TBL] [Abstract][Full Text] [Related]
15. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease.
Katz MH; Pisters PW; Evans DB; Sun CC; Lee JE; Fleming JB; Vauthey JN; Abdalla EK; Crane CH; Wolff RA; Varadhachary GR; Hwang RF
J Am Coll Surg; 2008 May; 206(5):833-46; discussion 846-8. PubMed ID: 18471707
[TBL] [Abstract][Full Text] [Related]
16. Multimodality management of borderline resectable pancreatic adenocarcinoma.
Prakash LR; Katz MHG
Chin Clin Oncol; 2017 Jun; 6(3):27. PubMed ID: 28705004
[TBL] [Abstract][Full Text] [Related]
17. Prediction of margin-negative resection of pancreatic ductal adenocarcinoma following neoadjuvant therapy: Diagnostic performance of NCCN criteria for resection vs CT-determined resectability.
Jang JK; Choi SJ; Byun JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Hwang DW; Kim SC
J Hepatobiliary Pancreat Sci; 2022 Sep; 29(9):1025-1034. PubMed ID: 35658103
[TBL] [Abstract][Full Text] [Related]
18. Treatment of borderline resectable pancreatic cancer.
Cooper AB; Tzeng CW; Katz MH
Curr Treat Options Oncol; 2013 Sep; 14(3):293-310. PubMed ID: 23793524
[TBL] [Abstract][Full Text] [Related]
19. Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer.
Shaib WL; Ip A; Cardona K; Alese OB; Maithel SK; Kooby D; Landry J; El-Rayes BF
Oncologist; 2016 Feb; 21(2):178-87. PubMed ID: 26834159
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic Accuracy of CT for Evaluating Circumferential Resection Margin Status in Resectable or Borderline Resectable Pancreatic Head Cancer: A Prospective Study Using Axially Sliced Surgical Pathologic Correlation.
Park JH; Yoon YS; Lee S; Kim HY; Han HS; Lee JS; Chang W; Kim H; Na HY; Han S; Lee KH
Korean J Radiol; 2022 Mar; 23(3):322-332. PubMed ID: 35029083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
